S&P 500   4,566.99 (+0.27%)
DOW   35,566.83 (+0.42%)
QQQ   390.63 (+0.11%)
AAPL   189.26 (-0.60%)
MSFT   378.79 (-1.02%)
META   332.46 (-1.93%)
GOOGL   135.18 (-1.47%)
AMZN   146.62 (-0.28%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.97 (-2.31%)
AMD   124.38 (+1.94%)
T   16.28 (+0.62%)
F   10.65 (+2.70%)
MU   76.80 (+0.89%)
CGC   0.56 (+4.28%)
GE   119.22 (+0.31%)
DIS   93.19 (+0.75%)
AMC   7.18 (+7.16%)
PFE   30.10 (+1.38%)
PYPL   58.24 (-0.39%)
XOM   103.70 (-0.19%)
S&P 500   4,566.99 (+0.27%)
DOW   35,566.83 (+0.42%)
QQQ   390.63 (+0.11%)
AAPL   189.26 (-0.60%)
MSFT   378.79 (-1.02%)
META   332.46 (-1.93%)
GOOGL   135.18 (-1.47%)
AMZN   146.62 (-0.28%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.97 (-2.31%)
AMD   124.38 (+1.94%)
T   16.28 (+0.62%)
F   10.65 (+2.70%)
MU   76.80 (+0.89%)
CGC   0.56 (+4.28%)
GE   119.22 (+0.31%)
DIS   93.19 (+0.75%)
AMC   7.18 (+7.16%)
PFE   30.10 (+1.38%)
PYPL   58.24 (-0.39%)
XOM   103.70 (-0.19%)
S&P 500   4,566.99 (+0.27%)
DOW   35,566.83 (+0.42%)
QQQ   390.63 (+0.11%)
AAPL   189.26 (-0.60%)
MSFT   378.79 (-1.02%)
META   332.46 (-1.93%)
GOOGL   135.18 (-1.47%)
AMZN   146.62 (-0.28%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.97 (-2.31%)
AMD   124.38 (+1.94%)
T   16.28 (+0.62%)
F   10.65 (+2.70%)
MU   76.80 (+0.89%)
CGC   0.56 (+4.28%)
GE   119.22 (+0.31%)
DIS   93.19 (+0.75%)
AMC   7.18 (+7.16%)
PFE   30.10 (+1.38%)
PYPL   58.24 (-0.39%)
XOM   103.70 (-0.19%)
S&P 500   4,566.99 (+0.27%)
DOW   35,566.83 (+0.42%)
QQQ   390.63 (+0.11%)
AAPL   189.26 (-0.60%)
MSFT   378.79 (-1.02%)
META   332.46 (-1.93%)
GOOGL   135.18 (-1.47%)
AMZN   146.62 (-0.28%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.97 (-2.31%)
AMD   124.38 (+1.94%)
T   16.28 (+0.62%)
F   10.65 (+2.70%)
MU   76.80 (+0.89%)
CGC   0.56 (+4.28%)
GE   119.22 (+0.31%)
DIS   93.19 (+0.75%)
AMC   7.18 (+7.16%)
PFE   30.10 (+1.38%)
PYPL   58.24 (-0.39%)
XOM   103.70 (-0.19%)

AC Immune Stock Price, News & Analysis (NASDAQ:ACIU)

$3.20
0.00 (0.00%)
(As of 01:40 PM ET)
Compare
Today's Range
$3.03
$3.21
50-Day Range
$2.46
$3.24
52-Week Range
$1.68
$3.83
Volume
28,047 shs
Average Volume
346,323 shs
Market Capitalization
$267.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

AC Immune MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
400.0% Upside
$16.00 Price Target
Short Interest
Bearish
1.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.68) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

801st out of 949 stocks

Pharmaceutical Preparations Industry

387th out of 437 stocks


ACIU stock logo

About AC Immune Stock (NASDAQ:ACIU)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ACIU Stock Price History

ACIU Stock News Headlines

AC Immune SA ACIU
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Are Medical Stocks Lagging AC Immune (ACIU) This Year?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
H.C. Wainwright Keeps Their Buy Rating on AC Immune SA (ACIU)
AC Immune SA Appoints New Chief Medical Officer
Ac Immune (NASDAQ: ACIU)
Why Shares of AC Immune Jumped This Week
AC Immune SA (ACIU) Gets a Buy from H.C. Wainwright
See More Headlines
Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACIU
Employees
126
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+401.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-74,140,000.00
Pretax Margin
-7,417,700.00%

Debt

Sales & Book Value

Annual Sales
$4.12 million
Book Value
$1.70 per share

Miscellaneous

Free Float
79,773,000
Market Cap
$266.75 million
Optionable
Not Optionable
Beta
0.72
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Andrea Pfeifer Ph.D. (Age 66)
    Co-Founder, CEO & Director
    Comp: $1.1M
  • Mr. Christopher Roberts (Age 34)
    Interim CFO & VP of Finance
  • Mr. Piergiorgio Donati (Age 52)
    Chief Technical Operations Officer
  • Dr. Marie Kosco-Vilbois (Age 65)
    Chief Scientific Officer
  • Mr. Jean-Fabien Monin (Age 52)
    Chief Administrative Officer
  • Mr. Howard Donovan (Age 48)
    Chief HR Officer
  • Mr. Joshua Drumm Ph.D.
    Head of Investor Relations
  • Mr. Alexandre Caratsch (Age 57)
    General Counsel
  • Judith Moore
    Global Head of Communications
  • Mr. Julian Snow
    VP of U.S. Finance & Corporate Development














ACIU Stock Analysis - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings
or view top-rated stocks.

What is AC Immune's stock price target for 2024?

1 Wall Street analysts have issued 12-month price targets for AC Immune's shares. Their ACIU share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for ACIU
or view top-rated stocks among Wall Street analysts.

How have ACIU shares performed in 2023?

AC Immune's stock was trading at $2.04 at the beginning of 2023. Since then, ACIU stock has increased by 56.9% and is now trading at $3.20.
View the best growth stocks for 2023 here
.

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ACIU earnings forecast
.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings data on Friday, November, 3rd. The company reported ($0.20) earnings per share for the quarter.

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?
When did AC Immune IPO?

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's stock is owned by a number of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (3.55%), Tower Research Capital LLC TRC (0.02%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACIU) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -